fpr2 agonist 3

Compound CMC23, an FPR2 agonist, mitigates lactate dehydrogenase release in LPS-stimulated cultures and reduces pro-inflammatory IL-1β and IL-6 levels. It also attenuates phosphor-STAT3 levels through the STAT3 SOCS3 signaling pathway [1].

ACT-389949 is a potent and selective agonist of formyl peptide receptor type 2 (FPR2) Lipoxin A4 receptor (ALX), with an EC50 of 3 nM for FPR2 ALX internalization into monocytes. It has the potential for the treatment of inflammatory disorders.

FPR2 agonist 2 is a potent FPR2 agonist with blood-brain barrier permeability that acts on h-FPR2 (EC50: 0.13 nM), inhibiting the production of pro-inflammatory cytokines, counteracting changes in mitochondrial function, and inhibiting caspase-3 activity.

MMK1 TFA is a potent, selective agonist for the human formyl peptide receptor like-1 (FPRL-1 FPR2), exhibiting EC50 values of <2 nM for FPRL-1 and >10,000 nM for FPR1. This compound acts as a powerful chemotactic and calcium-mobilizing agent, effectively activating phagocytic leukocytes. It significantly enhances the Pertussis Toxin-sensitive production of proinflammatory cytokines IL-1b and IL-6 by human monocytes. Additionally, MMK1 TFA has been demonstrated to exhibit anxiolytic-like activity [1] [2] [3] [4].